Amplia Therapeutics Limited
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) is an Australian clinical-stage biopharmaceutical company that develops focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis; its lead product candidate, narmafotinib (AMP945), a potent, selective, orally bioavailable small molecule FAK inhibitor, advances in Phase 1b/2a clinical trials including the ACCENT trial for advanced pancreatic cancer, the AMPLICITY trial combining narmafotinib with FOLFIRINOX chemotherapy, and studies in ovarian cancer and idiopathic pulmonary fibrosis; the company also develops AMP886, a multi-targeted inhibitor addressing FAK, VEGFR3, and FLT3 pathways for oncology and fibrosis indications. Founded in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics operates primarily in Australia with expanding clinical trial activities in the United States, targeting fibrotic cancers such as pancreatic and ovarian as well as chronic fibrotic diseases. In July 2025, the company completed a A$25 million institutional placement and A$2.5 million share purchase plan to fund ongoing ACCENT and AMPLICITY trials through 2027 and prepare for a potential Phase 2b/3 pivotal trial in late 2026; in October 2025, Amplia uplisted to the U.S. OTCQB Venture Market under ticker INNMF to enhance access for American investors amid growing interest in FAK inhibitors and pancreatic cancer therapies; on December 2, 2025, it secured a key U.S. patent for a novel salt and crystal form of narmafotinib extending protection to at least 2040; formerly known as Innate Immunotherapeutics Limited, the company rebranded to Amplia Therapeutics in September 2018.
Amplia Announces Publication of New FAK Inhibitor Patent Application
Amplia Announces Appointment of Brett Carter to Board
Amplia Announces Changes to Board's Leadership Roles
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
Accent Trial Mature Data Presented at International Conference
Altona Rare Earths shares jump 11% as gallium results exceed expectations at Mozambique project
Amplia flags key ACCENT milestone as 5 complete responses sharpen narmafotinib case in pancreatic cancer
X‑Energy files to go public on the Nasdaq, eyes $300M raise
Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
Additional Confirmed Response Reported as Part of Amplia Investor Presentation